8-K: Disc Medicine Presents Promising Clinical Data Updates at ASH 2024, Outlines Path Forward for Key Programs

Disc Medicine presented updated clinical data for bitopertin, DISC-0974, and DISC-3405 at the 66th American Society of Hematology Annual Meeting, highlighting progress and future plans for their hematology-focused pipeline.

Summary

• Disc Medicine held a conference call and webcast on December 8, 2024, to discuss data presented at the American Society of Hematology (ASH) Annual Meeting.
• The company provided updates on bitopertin for Erythropoietic Protoporphyria (EPP), DISC-0974 for anemia of myelofibrosis (MF) and other inflammatory anemias, and DISC-3405 for polycythemia vera (PV) and sickle cell disease (SCD).
• Bitopertin showed strong data in EPP, with a potential path to accelerated approval, and the confirmatory APOLLO study is planned to start by mid-2025.
• DISC-0974 demonstrated positive impacts on anemia in MF patients, with a Phase 2 study initiated, and showed promise in preclinical studies for anemia of inflammatory bowel disease (IBD) and chronic kidney disease (CKD).
• DISC-3405 showed deep reductions in serum iron and positive preclinical data in SCD, with a Phase 2 study in PV planned for 2025.
• The company has a strong cash position with a runway into 2027.

Sentiment

Score: 9

Explanation: The document is highly positive, highlighting strong clinical data, regulatory progress, and a clear path forward for the company's pipeline. The tone is optimistic and confident, suggesting a high likelihood of success.

Positives

• Bitopertin has a clear path to potential accelerated approval for EPP, supported by positive feedback from the FDA.
• DISC-0974 has shown efficacy across different types of MF patients, including those on JAK inhibitors, and has potential for broader use in anemias of inflammation.
• DISC-3405 has demonstrated a strong mechanism of action with deep reductions in serum iron and has potential for use in PV and SCD.
• The company has a strong cash position and a clear timeline for upcoming milestones.

Negatives

• The document does not explicitly mention any negative results or setbacks.
• The document focuses on positive data and future plans, without highlighting any specific risks or challenges.

Risks

• The document includes a standard disclaimer about forward-looking statements, noting that actual results could differ materially due to various risks and uncertainties.
• The company's ability to successfully initiate and complete clinical trials is subject to risks.
• The timing and cost of development of the company's product candidates are difficult to predict.
• The results of preclinical studies and clinical trials may not be predictive of future results.

Future Outlook

The company anticipates multiple data catalysts in the next 18 months, including the initiation of the APOLLO study for bitopertin, initial Phase 2 data for DISC-0974 in MF, and Phase 2a study initiation for DISC-3405 in PV. Guidance on NDA timing for bitopertin will be provided in Q1 2025.

Management Comments

• John Quisel, JD, PhD, Chief Executive Officer, provided an introduction and summary of the company's programs.
• Will Savage, MD, PhD, Chief Medical Officer, reviewed updated data and regulatory paths for bitopertin, DISC-0974, and DISC-3405.
• Pamela Stephenson, MPH, Chief Commercial Officer, discussed the EPP market opportunity and commercialization approach.

Industry Context

This announcement highlights Disc Medicine's progress in developing treatments for rare hematological diseases, aligning with the industry's focus on targeted therapies and addressing unmet medical needs. The company's approach to hepcidin modulation and heme biosynthesis is innovative and could potentially disrupt the treatment landscape for these conditions.

Comparison to Industry Standards

• Bitopertin's results in EPP, particularly the reduction in PPIX and improvement in light tolerance, are comparable to or better than other investigational therapies in this space, such as those targeting heme biosynthesis.
• DISC-0974's efficacy in MF, including the response rates in both transfusion-dependent and non-transfusion-dependent patients, is competitive with other emerging therapies targeting anemia in myelofibrosis, such as those using hepcidin modulation or erythropoiesis-stimulating agents.
• The deep reductions in serum iron observed with DISC-3405 are notable and could position it as a potential treatment for iron overload disorders, where current therapies often have limitations. The preclinical data in SCD also suggests a novel approach compared to traditional treatments.
• Companies like Protagonist Therapeutics and Keros Therapeutics are also developing hepcidin-modulating therapies, but Disc Medicine's approach with monoclonal antibodies and small molecules offers a differentiated strategy.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical data and clear development plans.
• Patients with EPP, MF, PV, and SCD may benefit from the development of these new therapies.
• Employees of Disc Medicine are likely to be motivated by the company's progress and future prospects.
• The company's success could lead to increased collaboration with research institutions and other pharmaceutical companies.

Next Steps

• The company will provide guidance on NDA timing for bitopertin in Q1 2025.
• The APOLLO study for bitopertin is planned to start by mid-2025.
• The Phase 2 study for DISC-0974 in MF has been initiated, with initial data expected in H2 2025.
• The Phase 1b multiple-dose portion of the CKD anemia study will be initiated by the end of the year, with data expected by the end of 2025.
• The Phase 2 study for DISC-3405 in PV is planned to start in the first half of 2025.

Key Dates

Keywords

Bitopertin, DISC-0974, DISC-3405, Erythropoietic Protoporphyria, Myelofibrosis, Anemia, Polycythemia Vera, Sickle Cell Disease, Hepcidin, Hematology, Clinical Trials, ASH, FDA, Accelerated Approval